ASH Annual Meeting & Exposition: Leukemia

Following a fixed-treatment duration of ibrutinib combined with venetoclax achieved similar 1-year disease-free survival in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.

Treatment with the combination regimen improved progression-free survival (PFS) and overall survival (OS) over a 5-year period compared with patients treated with bendamustine and rituximab.

Naval Daver, MD, explains the progress made on 3 abstracts he’s involved with regarding acute myeloid leukemia (AML) at the ASH Annual Meeting and Exposition.

Courtney DiNardo, MD, MSCE, elaborated on interim phase II results regarding enasibenib plus azacitidine in patients with newly diagnosed acute myeloid leukemia, and the results from the QUAZAR trial.

The combination of ibrutinib and rituximab demonstrated superior progression-free survival in older patients with previously untreated chronic lymphocytic leukemia.

The triplet regimen consisting of acalabrutinib, venetoclax, and obinutuzumab appeared highly active as frontline therapy for patients with chronic lymphocytic leukemia.

Acalabrutinib alone and in combination with obinutuzumab significantly improved progression-free survival, compared with obinutuzumab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia

First-line treatment with ibrutinib plus venetoclax provided high rates of undetectable minimal residual disease in peripheral blood and bone marrow of patients with chronic lymphocytic leukemia.

In an interview with Cancer Network, Brad S. Kahl, MD, weighs in on the top CLL research presented at ASH 2018 in San Diego.

Researchers analyzed a new recurrent BCL2 mutation appearing in a cohort of patients with CLL-type progressions treated with venetoclax.

Leukemia cells show sensitivity to restriction of BCL2 and BTK with the combination of venetoclax and ibrutinib.

Allogeneic hematopoietic stem cell transplantation could improve outcomes of elderly patients with acute myeloid leukemia.

Researchers used high throughput drug screening on leukemic stem cells to determine drug resistance and sensitivity in acute myeloid leukemia patients.

Acalabrutinib continues to yield high response rates in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

The novel agent ivosidenib is well tolerated and induces durable responses in patients with relapsed/refractory acute myeloid leukemia and other hematologic malignancies.

Next-generation sequencing could be a powerful and independent predictor for relapse and survival among adults with acute myeloid leukemia.

A combination of ibrutinib plus standard chemoimmunotherapy induces deep responses in a relatively high-risk group of previously untreated, young chronic lymphocytic leukemia patients, according to a new study.

Adults with Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia are very likely to achieve complete response with intensive combination induction chemotherapy, according to a retrospective review presented at the ASH Annual Meeting.

About one-third of patients with previously treated chronic lymphocytic leukemia (CLL) were minimal residual disease negative after 6 months of treatment with the combination of targeted agents ibrutinib and venetoclax, according to the results of the TAP CLARITY study.

Hospice use occurred more frequently among Medicare beneficiaries with acute and chronic leukemias who were transfusion dependent, according to the results of a study presented at the ASH Annual Meeting.

In this interview ahead of the ASH Annual Meeting we discuss the current management of Philadelphia chromosome–positive acute lymphoblastic leukemia and the role of stem cell transplantation.

Among pediatric acute lymphoblastic leukemia patients who have favorable prognosis, an attempt to reduce the burden of chemotherapy by using lower intensity delayed intensification failed to show better outcomes.

T-cell therapy targeting CD22, a protein found on the surface of leukemic cells, was safe and feasible in a small and ongoing study of patients with ALL.

Many patients with stable CML may be able to safely decrease their dose of tyrosine kinase inhibitor to half of the standard dose and improve TKI-related side effects, according to the results of the DESTINY trial.

Older patients with AML survive longer after receiving an allogeneic stem cell transplant if they are initially treated with CPX-351 liposome injection instead of the standard “7+3” chemotherapy with cytarabine and daunorubicin.

Cessation of tyrosine kinase inhibitor therapy may be possible in chronic myeloid leukemia patients with deep molecular response, according to the results of the Euro-Ski trial.

In this interview we discuss prognostic models that may be able to predict disease progression in patients with chronic lymphocytic leukemia treated with the targeted agent ibrutinib.

Combining standard chemotherapy with vadastuximab talirine was safe and well-tolerated in newly diagnosed acute myeloid leukemia.